ESMO Asia Congress 2022
![Asia Congress 2022_audience](/var/esmo/storage/images/media/esmo-daily-reporter/images/asia-2022/asia-congress-2022_audience/16092918-1-eng-GB/asia-congress-2022_audience_i770.jpg)
Benefits of immunotherapy in hepatocellular carcinoma are confirmed in Asian subpopulations
New subpopulation analyses from three international phase III trials confirm efficacy of immune checkpoint inhibitors across geographical areas
![Presidential_Tony Mok](/var/esmo/storage/images/media/esmo-daily-reporter/images/asia-2022/presidential_tony-mok/16096608-1-eng-GB/presidential_tony-mok_i770.jpg)
Nivolumab plus chemotherapy does not improve PFS in EGFR-mutated NSCLC
CheckMate 722 trial fails to meet its primary endpoint in patients with cancer progressing on one or two prior lines of EGFR tyrosine-kinase inhibitors
![Presidential_general](/var/esmo/storage/images/media/esmo-daily-reporter/images/asia-2022/presidential_general/16096623-3-eng-GB/presidential_general_i770.jpg)
Hepatocellular carcinoma: apatinib after transarterial chemoembolisation prolongs PFS in a Chinese population
Positive results in intermediate and advanced disease come after the failure of global trials investigating the combination of TACE with targeted agents
![DR_mobile_FOR EDITORIALS](/var/esmo/storage/images/media/esmo-daily-reporter/images/dr_mobile_for-editorials/12211793-1-eng-GB/dr_mobile_for-editorials_i770.jpg)
National cancer registries in Asia – is Big Data the way to go?
Integrated, comprehensive databases may help to close the gap in cancer care between high- and low-/lower-middle-income countries
![Asia Congress 2022_venue](/var/esmo/storage/images/media/esmo-daily-reporter/images/asia-2022/asia-congress-2022_venue/16092744-1-eng-GB/asia-congress-2022_venue_i770.jpg)
Serplulimab plus chemotherapy prolongs progression-free survival in PD-L1-positive oesophageal squamous cell carcinoma
Final overall survival results are now awaited to confirm the place of the combination treatment as a standard approach
![Asia Congress 2022_session](/var/esmo/storage/images/media/esmo-daily-reporter/images/asia-2022/asia-congress-2022_session/16092774-1-eng-GB/asia-congress-2022_session_i770.jpg)
New PAGAs on endometrial cancer and metastatic breast cancer presented in Singapore
Differences in cancer population, local expertise, availability of and accessibility to treatments are incorporated into two new Pan-Asian adaptations (PAGA) of the ESMO Clinical Practice Guidelines
![De Rosa_Developmental](/var/esmo/storage/images/media/esmo-daily-reporter/images/asia-2022/de-rosa_developmental/16092729-2-eng-GB/de-rosa_developmental_i770.jpg)
Test for gut microbiota predicts survival in patients receiving an immune checkpoint inhibitor
An easy-to-use method to detect dysbiosis may help guide selection of cancer treatments and microbiota-centred interventions
![Asia Congress 2022_venue 2](/var/esmo/storage/images/media/esmo-daily-reporter/images/asia-2022/asia-congress-2022_venue-2/16092759-1-eng-GB/asia-congress-2022_venue-2_i770.jpg)
Tobacco use is still a neglected cancer risk factor in Asia
Tailored strategies based on existing technologies and digital tools are needed to help inform people in geographically difficult-to-reach communities
![Jyoti Bajpai](/var/esmo/storage/images/media/esmo-daily-reporter/images/portraits/jyoti-bajpai/15965409-1-eng-GB/jyoti-bajpai_i770.jpg)
Rare cancers in Asia – the value of registry data in low-resourced settings
While some challenges associated with rare cancers are similar in Europe and Asia, resources and differing epidemiology need to be considered when coming up with solutions
![Janice Tsang](/var/esmo/storage/images/media/esmo-daily-reporter/images/portraits/janice-tsang/15965394-1-eng-GB/janice-tsang_i770.jpg)
Equity among oncologists is far from being achieved in the Chinese culture
Results from a pilot study show that work–family balance is the biggest challenge to career progression for young women